

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.6	90.3	(33.0-196.6)	Male	7	4.6	152.7	(61.2-314.5)
Female	2	2.4	nc	(nc-nc)	Female	8	3.8	212.1	(91.3-418.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	26	27.2	95.5	(62.3-139.9)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	9.8	122.0	(62.9-213.1)	Female	3	2.7	nc	(nc-nc)
Female	11	8.7	127.0	(63.3-227.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.1	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	27.4	109.4	(73.8-156.3)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.3	nc	(nc-nc)	Female	8	6.0	133.2	(57.4-262.6)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	95	94.8	100.2	(81.0-122.5)
Male	1	1.8	nc	(nc-nc)	Female	95	89.5	106.2	(85.9-129.8)
Female	2	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	12.7	86.5	(43.1-154.8)					
Female	11	11.9	92.7	(46.2-165.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	19.6	127.5	(82.5-188.2)	Male	18	12.6	143.0	(84.7-226.1)
Female	4	8.0	nc	(nc-nc)	Female	22	11.2	196.4	(123.0-297.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.7	74.9	(32.2-147.6)
Female	74	80.6	91.8	(72.1-115.3)	Female	12	10.4	115.4	(59.6-201.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	4	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	28.1	117.4	(80.8-164.8)	Female	8	8.3	96.0	(41.3-189.1)
Female	30	29.4	102.0	(68.8-145.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.0	82.7	(26.6-193.0)
Male	8	5.3	151.3	(65.1-298.1)	Female	4	6.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	84	76.0	110.5	(88.1-136.8)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.2	nc	(nc-nc)
Male	14	9.6	145.7	(79.6-244.5)	<u>Testis</u>				
Female	5	6.4	78.6	(25.3-183.5)	Male	0	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.3	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	8	10.9	73.3	(31.6-144.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.4	124.6	(53.6-245.5)	Female	14	17.9	78.2	(42.7-131.2)
Female	4	5.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	283	266.1	106.4	(94.3-119.5)
Male	5	4.8	103.7	(33.4-242.0)	Female	264	277.4	95.2	(84.0-107.4)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	36.5	93.0	(64.4-130.0)					
Female	45	37.9	118.7	(86.5-158.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	104	101.1	102.9	(84.0-124.6)	Male	81	60.6	133.7	(106.2-166.1)
Female	35	37.8	92.5	(64.4-128.7)	Female	72	50.8	141.9	(111.0-178.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	17.7	101.5	(60.1-160.5)	Male	20	15.6	127.9	(78.1-197.5)
Female	13	15.6	83.1	(44.2-142.1)	Female	11	12.1	91.2	(45.4-163.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.2	nc	(nc-nc)	Male	66	52.3	126.3	(97.6-160.6)
Female	422	361.8	116.6	(105.8-128.3)	Female	53	48.8	108.6	(81.3-142.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	15.2	46.1	(18.5-95.1)	Male	20	36.9	54.2	(33.1-83.7)
Female					Female	22	18.3	120.5	(75.5-182.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	128	140.6	91.0	(75.9-108.2)	Female	44	38.1	115.6	(84.0-155.2)
Female	122	139.3	87.6	(72.7-104.5)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	25.6	58.5	(32.7-96.5)	Male	29	30.3	95.8	(64.2-137.6)
Female	6	7.4	81.5	(29.8-177.5)	Female	32	32.9	97.1	(66.4-137.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.5	66.3	(21.4-154.7)	Male	408	365.3	111.7	(101.1-123.1)
Female	4	6.5	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	49	45.8	107.0	(79.1-141.4)	Male	23	23.3	98.7	(62.5-148.1)
Female	36	29.5	122.2	(85.6-169.1)	Female	10	15.3	65.5	(31.4-120.5)
<u>Larynx</u>					<u>Testis</u>				
Male	10	15.8	63.4	(30.4-116.6)	Male	17	12.0	141.6	(82.4-226.7)
Female	4	4.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	21	32.4	64.8	(40.1-99.0)	Male	31	14.7	211.6	(143.7-300.3)
Female	26	26.3	98.8	(64.5-144.8)	Female	74	48.0	154.3	(121.2-193.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	22.7	70.4	(40.2-114.4)	Female	97	80.3	120.8	(97.9-147.3)
Female	2	8.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	116	183.9	63.1	(52.1-75.7)	Male	1289	1307.1	98.6	(93.3-104.2)
Female	134	179.4	74.7	(62.6-88.5)	Female	1305	1278.6	102.1	(96.6-107.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.7	117.5	(53.6-223.1)	Male	8	6.7	118.9	(51.2-234.2)
Female	5	1.9	264.1	(85.1-616.2)	Female	5	3.8	132.1	(42.6-308.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	36	26.4	136.4	(95.5-188.8)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	12.4	88.8	(44.3-159.0)	Female	3	2.6	nc	(nc-nc)
Female	5	7.0	71.9	(23.2-167.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	2.6	273.3	(109.5-563.1)
Male	4	2.4	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	34.4	104.5	(73.2-144.7)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	12	4.4	271.9	(140.3-475.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.1	nc	(nc-nc)	Female	9	5.7	158.1	(72.2-300.2)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	119	123.8	96.1	(79.6-115.0)
Male	1	2.5	nc	(nc-nc)	Female	118	81.5	144.8	(119.8-173.3)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	15.2	79.2	(40.9-138.3)					
Female	15	9.7	154.6	(86.5-255.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.5	108.6	(65.3-169.5)	Male	10	10.1	98.6	(47.2-181.4)
Female	5	7.7	65.3	(21.0-152.4)	Female	3	8.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.8	79.5	(31.8-163.8)
Female	45	63.7	70.7	(51.5-94.6)	Female	10	9.5	105.1	(50.3-193.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.4	204.3	(65.8-476.7)	Male	9	6.0	149.7	(68.3-284.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	23.9	100.5	(64.4-149.6)	Female	7	6.9	101.3	(40.6-208.7)
Female	28	28.0	100.1	(66.5-144.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	7	4.3	161.3	(64.6-332.3)	Male	88	62.2	141.5	(113.5-174.3)
Female	5	1.5	334.3	(107.7-780.2)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.7	104.2	(44.8-205.2)	Female	12	14.2	84.7	(43.7-147.9)
Female	5	5.6	89.7	(28.9-209.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Male	281	222.6	126.3	(111.9-141.9)
Female	1	0.8	nc	(nc-nc)	Female	226	239.1	94.5	(82.6-107.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.5	108.7	(39.7-236.5)	<u>All Sites / Types</u>				
Female	4	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	54	31.9	169.1	(127.0-220.6)	<u>All Sites / Types</u>				
Female	48	35.7	134.6	(99.2-178.5)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	27.9	118.4	(81.5-166.2)	Male	19	17.6	108.0	(65.0-168.7)
Female	16	11.5	139.6	(79.8-226.8)	Female	24	15.3	156.6	(100.3-233.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.4	166.4	(76.0-316.0)	Male	5	4.4	113.9	(36.7-265.9)
Female	4	4.8	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	10	15.1	66.0	(31.6-121.4)
Female	122	107.2	113.8	(94.5-135.9)	Female	12	14.8	80.9	(41.8-141.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.6	nc	(nc-nc)	Male	11	10.8	102.0	(50.9-182.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	39.4	91.3	(63.9-126.4)	Female	18	11.4	158.4	(93.8-250.4)
Female	36	43.2	83.3	(58.3-115.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	8.4	71.1	(26.0-154.9)
Male	15	7.2	208.1	(116.4-343.3)	Female	10	10.1	99.2	(47.5-182.5)
Female	3	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	113	101.4	111.5	(91.9-134.0)
Male	1	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	10	6.5	153.6	(73.5-282.5)
<u>Kidney & Renal Pelvis</u>					Female	4	4.8	nc	(nc-nc)
Male	10	13.1	76.1	(36.4-140.0)	<u>Testis</u>				
Female	9	8.7	103.0	(47.0-195.6)	Male	3	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.4	112.8	(36.3-263.2)	Male	4	4.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	10	14.5	69.0	(33.0-127.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.5	84.4	(36.3-166.3)	Female	24	23.2	103.4	(66.2-153.9)
Female	6	8.3	72.6	(26.5-158.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	381	368.4	103.4	(93.3-114.3)
Male	2	6.5	nc	(nc-nc)	Female	413	384.1	107.5	(97.4-118.4)
Female	2	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	50.5	85.1	(61.6-114.6)					
Female	50	52.7	94.9	(70.4-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	23.1	60.5	(33.1-101.5)	Male	17	16.2	104.9	(61.1-167.9)
Female	8	8.6	92.7	(39.9-182.6)	Female	17	14.2	119.3	(69.5-191.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	134.6	(53.9-277.3)	Male	2	3.8	nc	(nc-nc)
Female	7	4.4	160.8	(64.4-331.4)	Female	5	2.8	181.0	(58.3-422.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	20	13.7	146.3	(89.3-226.0)
Female	121	95.7	126.4	(104.9-151.1)	Female	7	11.8	59.2	(23.7-121.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.8	nc	(nc-nc)	Male	6	10.2	59.1	(21.6-128.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	33.9	100.2	(69.4-140.0)	Female	6	9.8	61.3	(22.4-133.4)
Female	39	31.7	123.2	(87.6-168.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.2	nc	(nc-nc)
Male	4	6.4	nc	(nc-nc)	Female	6	7.4	80.8	(29.5-175.9)
Female	3	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	81	91.7	88.3	(70.1-109.7)
Male	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	5.5	91.6	(29.5-213.7)
<u>Kidney & Renal Pelvis</u>					Female	0	3.4	nc	(nc-nc)
Male	10	12.1	82.6	(39.5-151.8)	<u>Testis</u>				
Female	7	7.3	95.4	(38.2-196.6)	Male	3	4.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.0	nc	(nc-nc)	Male	5	4.6	108.3	(34.9-252.6)
Female	1	1.1	nc	(nc-nc)	Female	17	15.3	111.4	(64.8-178.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.4	nc	(nc-nc)	Female	19	20.9	90.9	(54.7-142.0)
Female	6	6.6	90.6	(33.1-197.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	315	327.8	96.1	(85.8-107.3)
Male	5	6.0	83.8	(27.0-195.5)	Female	356	322.4	110.4	(99.2-122.5)
Female	0	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	61	43.7	139.7	(106.9-179.5)					
Female	44	42.0	104.7	(76.0-140.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.1	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	18	18.4	97.8	(57.9-154.6)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	7.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	9	6.6	135.8	(62.0-257.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	18.8	53.2	(25.5-97.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	2.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	9.4	nc	(nc-nc)	Male	41	67.9	60.4	(43.3-81.9)
Female	4	9.0	nc	(nc-nc)	Female	55	63.9	86.1	(64.8-112.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.3	128.3	(74.7-205.4)	Male	9	9.1	99.1	(45.2-188.2)
Female	6	4.6	129.9	(47.4-282.8)	Female	10	7.3	137.4	(65.8-252.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.9	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.6	91.7	(36.7-188.9)
Female	57	51.8	110.0	(83.3-142.5)	Female	4	6.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	5	5.9	84.9	(27.3-198.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	19.4	72.2	(39.4-121.1)	Female	4	5.2	nc	(nc-nc)
Female	11	16.5	66.6	(33.2-119.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.2	nc	(nc-nc)
Male	5	3.7	133.4	(43.0-311.3)	Female	3	3.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	55.1	127.1	(99.1-160.6)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	13	7.0	185.7	(98.8-317.5)	<u>Testis</u>				
Female	4	4.0	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	10	7.7	130.5	(62.5-240.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.6	108.4	(34.9-253.0)	Female	6	11.6	51.8	(18.9-112.8)
Female	4	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	212	189.2	112.1	(97.5-128.2)
Male	1	3.5	nc	(nc-nc)	Female	172	171.8	100.1	(85.7-116.2)
Female	3	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	25.6	93.8	(60.1-139.5)					
Female	19	23.1	82.4	(49.6-128.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	30.6	81.6	(52.8-120.5)	Male	16	18.9	84.5	(48.3-137.2)
Female	13	12.5	103.6	(55.1-177.2)	Female	19	17.5	108.7	(65.4-169.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.5	nc	(nc-nc)	Male	9	4.8	187.6	(85.6-356.2)
Female	3	5.3	nc	(nc-nc)	Female	6	4.0	149.9	(54.7-326.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	15	16.2	92.5	(51.8-152.6)
Female	118	116.6	101.2	(83.8-121.2)	Female	17	16.4	103.5	(60.3-165.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.1	116.5	(42.6-253.7)	Male	11	11.6	94.6	(47.1-169.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	43.1	92.7	(66.2-126.3)	Female	9	12.6	71.6	(32.6-135.8)
Female	44	47.4	92.8	(67.5-124.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.2	64.9	(23.7-141.2)
Male	10	7.9	126.5	(60.6-232.7)	Female	16	11.0	144.9	(82.8-235.3)
Female	4	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	105	111.7	94.0	(76.9-113.8)
Male	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.8	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	5.3	nc	(nc-nc)
Male	12	14.2	84.3	(43.5-147.3)	<u>Testis</u>				
Female	9	9.5	94.5	(43.1-179.4)	Male	7	4.3	162.6	(65.1-334.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.8	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	13	16.8	77.6	(41.3-132.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.9	80.8	(34.8-159.2)	Female	28	25.4	110.1	(73.2-159.2)
Female	4	8.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	357	401.9	88.8	(79.8-98.5)
Male	5	7.1	70.3	(22.6-164.0)	Female	403	422.6	95.4	(86.3-105.2)
Female	1	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	50	55.9	89.5	(66.4-118.0)					
Female	53	57.6	92.0	(68.9-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.3	73.1	(33.3-138.7)	Male	7	8.8	79.9	(32.0-164.6)
Female	1	4.4	nc	(nc-nc)	Female	7	7.4	95.2	(38.1-196.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.8	211.8	(77.4-461.1)	Male	3	2.1	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
Female	58	51.3	113.0	(85.8-146.1)	Female	3	6.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.5	201.6	(65.0-470.5)	Male	5	5.7	87.3	(28.1-203.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	18.3	81.9	(45.8-135.1)	Female	5	5.2	97.0	(31.2-226.3)
Female	25	15.8	157.9	(102.1-233.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.9	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	51.8	113.8	(86.6-146.8)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.7	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.8	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	8.0	62.8	(20.2-146.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.4	nc	(nc-nc)	Female	13	11.3	115.1	(61.2-196.9)
Female	1	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	160	179.2	89.3	(76.0-104.2)
Male	3	3.4	nc	(nc-nc)	Female	180	167.9	107.2	(92.1-124.0)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	23.9	67.1	(38.3-108.9)					
Female	21	21.8	96.2	(59.5-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.1	91.9	(48.9-157.2)	Male	12	8.9	134.8	(69.6-235.5)
Female	3	5.9	nc	(nc-nc)	Female	5	7.9	63.6	(20.5-148.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.7	91.4	(36.6-188.4)
Female	62	54.2	114.3	(87.6-146.5)	Female	9	7.6	118.1	(53.9-224.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	6	5.4	111.4	(40.7-242.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	19.9	105.4	(65.2-161.1)	Female	5	5.8	86.6	(27.9-202.1)
Female	19	22.3	85.1	(51.2-132.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.3	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	50.9	100.2	(74.6-131.8)
Male	4	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.5	nc	(nc-nc)
Male	7	6.6	105.4	(42.2-217.3)	<u>Testis</u>				
Female	3	4.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	9	7.4	121.9	(55.6-231.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.8	104.3	(33.6-243.5)	Female	13	11.8	110.6	(58.8-189.1)
Female	3	4.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	176	186.0	94.6	(81.2-109.7)
Male	1	3.2	nc	(nc-nc)	Female	187	196.5	95.2	(82.0-109.8)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	25.6	85.8	(53.8-130.0)					
Female	30	27.0	111.1	(74.9-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	11	13.1	83.7	(41.7-149.7)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	6	4.7	129.0	(47.1-280.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	14.0	128.2	(75.9-202.5)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.7	nc	(nc-nc)	Female	8	2.9	273.4	(117.7-538.8)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Male	44	48.7	90.4	(65.7-121.4)
Female	0	0.2	nc	(nc-nc)	Female	47	45.0	104.5	(76.7-138.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	6.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	6.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	13.0	84.4	(42.1-151.0)	Male	8	9.7	82.9	(35.7-163.3)
Female	1	5.1	nc	(nc-nc)	Female	16	8.9	179.9	(102.8-292.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	8.1	61.6	(19.8-143.7)
Female	42	57.8	72.7	(52.4-98.3)	Female	9	7.1	126.6	(57.8-240.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	19.6	163.6	(111.9-230.9)	Female	5	6.0	84.0	(27.1-195.9)
Female	7	18.8	37.3	(14.9-76.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.1	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	53.7	102.5	(77.2-133.4)
Male	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.1	nc	(nc-nc)
Male	11	7.2	153.3	(76.4-274.3)	<u>Testis</u>				
Female	4	4.4	nc	(nc-nc)	Male	8	3.0	264.8	(114.0-521.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	9	9.8	91.7	(41.8-174.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.0	nc	(nc-nc)	Female	13	12.6	103.4	(55.0-176.8)
Female	3	4.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	204	191.5	106.5	(92.4-122.2)
Male	5	3.6	140.4	(45.3-327.8)	Female	179	194.3	92.1	(79.1-106.6)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	24.8	128.9	(88.2-182.0)					
Female	22	24.4	90.3	(56.5-136.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.7	119.8	(65.4-201.0)	Male	10	7.5	132.7	(63.5-244.1)
Female	2	4.2	nc	(nc-nc)	Female	14	5.9	235.6	(128.7-395.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.4	109.4	(43.8-225.4)
Female	37	43.7	84.6	(59.6-116.7)	Female	7	5.5	126.6	(50.7-260.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	5	5.0	100.8	(32.5-235.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	16.9	100.8	(58.7-161.4)	Female	5	4.5	110.9	(35.7-258.8)
Female	20	15.5	128.6	(78.5-198.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.6	nc	(nc-nc)
Male	5	3.2	154.9	(49.9-361.5)	Female	2	3.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	47.5	80.0	(56.6-109.9)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	6	5.8	102.7	(37.5-223.4)	<u>Testis</u>				
Female	9	3.4	264.5	(120.7-502.1)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	6	1.9	312.3	(114.0-679.8)
Female	0	0.5	nc	(nc-nc)	Female	10	5.8	173.3	(83.0-318.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.9	nc	(nc-nc)	Female	10	9.9	101.2	(48.4-186.1)
Female	6	3.0	200.6	(73.2-436.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	152	161.7	94.0	(79.7-110.2)
Male	3	2.9	nc	(nc-nc)	Female	157	148.7	105.6	(89.7-123.5)
Female	3	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	22.1	67.9	(38.0-112.0)					
Female	16	20.1	79.6	(45.5-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	36.4	60.5	(37.9-91.6)	Male	25	21.4	117.0	(75.7-172.7)
Female	16	14.5	110.2	(62.9-178.9)	Female	22	18.0	122.0	(76.5-184.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.2	177.1	(88.3-316.9)	Male	5	5.5	90.4	(29.1-210.9)
Female	9	5.6	160.6	(73.3-304.8)	Female	5	4.6	109.6	(35.3-255.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	15	18.4	81.3	(45.5-134.1)
Female	104	128.0	81.2	(66.4-98.4)	Female	15	18.2	82.3	(46.0-135.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.3	113.8	(41.6-247.8)	Male	12	12.6	95.2	(49.1-166.3)
Female	6	5.3	113.8	(41.6-247.8)	Female	6	6.7	90.1	(32.9-196.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	49.8	130.5	(100.7-166.4)	Female	19	13.6	139.2	(83.8-217.4)
Female	48	52.9	90.7	(66.9-120.3)	Female	19	13.6	139.2	(83.8-217.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.1	121.5	(60.6-217.5)	Male	11	10.8	102.1	(50.9-182.7)
Female	2	2.8	nc	(nc-nc)	Female	9	12.6	71.6	(32.6-135.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	132	128.8	102.5	(85.7-121.5)
Female	2	2.2	nc	(nc-nc)	Male	132	128.8	102.5	(85.7-121.5)
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	17	16.1	105.4	(61.3-168.7)	Male	5	8.3	60.0	(19.3-140.1)
Female	11	10.9	101.2	(50.5-181.1)	Female	11	5.9	187.3	(93.4-335.1)
<u>Larynx</u>					<u>Testis</u>				
Male	10	5.5	180.4	(86.4-331.9)	Male	7	4.5	155.7	(62.4-320.7)
Female	2	1.6	nc	(nc-nc)	Male	7	4.5	155.7	(62.4-320.7)
<u>Leukemia</u>					<u>Thyroid</u>				
Male	12	11.5	104.3	(53.8-182.2)	Male	2	5.1	nc	(nc-nc)
Female	13	9.9	132.0	(70.2-225.7)	Female	15	16.3	92.1	(51.5-151.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	7.8	77.0	(28.1-167.6)	Female	30	28.5	105.2	(71.0-150.2)
Female	4	3.1	nc	(nc-nc)	Female	30	28.5	105.2	(71.0-150.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	67	66.2	101.3	(78.5-128.6)	Male	467	463.4	100.8	(91.8-110.3)
Female	86	68.3	126.0	(100.8-155.6)	Female	476	468.2	101.7	(92.7-111.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.2	143.5	(52.4-312.4)	Male	4	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	19	16.6	114.3	(68.8-178.6)	Female	2	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.9	100.9	(36.8-219.6)	Female	1	1.7	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	15.9	145.0	(91.9-217.6)
Male	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	1.4	434.5	(158.7-945.8)	Female	1	3.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	77	56.3	136.7	(107.9-170.9)
Male	1	1.0	nc	(nc-nc)	Female	58	58.8	98.6	(74.9-127.5)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	7.8	127.8	(61.2-235.1)					
Female	6	8.5	70.7	(25.8-154.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	6.1	97.6	(35.7-212.5)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	21	22.0	95.6	(59.2-146.2)
Male	0	0.4	nc	(nc-nc)	Female	12	18.5	64.7	(33.4-113.0)
Female	0	0.1	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	5	2.9	174.7	(56.3-407.6)	<u>Male</u>				
Female	0	2.2	nc	(nc-nc)	<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.5	129.5	(64.5-231.7)	Male	3	5.3	nc	(nc-nc)
Female	6	3.2	188.8	(68.9-411.0)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.5	110.6	(35.6-258.1)
Female	17	30.9	55.0	(32.0-88.0)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	12.0	50.1	(18.3-109.0)	Female	0	3.2	nc	(nc-nc)
Female	9	11.5	78.1	(35.6-148.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	32.7	73.4	(47.0-109.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	4.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	2.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.0	nc	(nc-nc)	Female	10	7.0	143.1	(68.5-263.2)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	15	15.9	94.1	(52.6-155.1)	Male	81	113.9	71.1	(56.5-88.4)
Female	14	15.3	91.3	(49.9-153.2)	Female	81	108.7	74.5	(59.2-92.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	16.8	160.6	(105.8-233.7)	Male	13	8.4	155.5	(82.7-266.0)
Female	7	5.9	118.0	(47.3-243.2)	Female	6	5.7	104.6	(38.2-227.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.4	94.8	(38.0-195.3)
Female	55	45.0	122.1	(92.0-159.0)	Female	10	7.0	141.9	(68.0-261.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	6	4.8	125.9	(46.0-274.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	21.9	96.1	(59.5-146.9)	Female	4	4.9	nc	(nc-nc)
Female	18	21.4	84.2	(49.9-133.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	4.8	145.8	(58.4-300.5)
Male	2	3.9	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	87	56.0	155.4	(124.4-191.6)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.4	nc	(nc-nc)
Male	7	6.5	107.9	(43.2-222.3)	<u>Testis</u>				
Female	4	4.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	4.7	214.8	(102.8-395.0)	Female	14	10.3	135.5	(74.0-227.3)
Female	3	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	246	197.6	124.5	(109.4-141.0)
Male	3	3.1	nc	(nc-nc)	Female	179	173.6	103.1	(88.6-119.4)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	30.1	76.5	(48.5-114.8)					
Female	23	27.7	83.0	(52.6-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.9	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	5	8.0	62.5	(20.2-146.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	1.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	3.8	nc	(nc-nc)	Male	28	27.2	102.9	(68.4-148.7)
Female	3	2.7	nc	(nc-nc)	Female	18	19.2	93.7	(55.5-148.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	12.6	127.4	(72.8-206.9)	Male	5	8.4	59.2	(19.1-138.2)
Female	7	4.6	151.8	(60.8-312.8)	Female	5	7.2	69.3	(22.3-161.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	5	2.2	226.2	(72.9-527.8)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	12	7.2	167.8	(86.6-293.1)
Female	56	49.7	112.7	(85.1-146.3)	Female	6	6.2	96.7	(35.3-210.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	9	5.3	170.1	(77.6-323.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	18.2	77.1	(42.1-129.4)	Female	4	5.1	nc	(nc-nc)
Female	15	16.6	90.5	(50.6-149.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.9	180.5	(72.3-371.9)
Male	5	3.4	146.5	(47.2-341.9)	Female	4	3.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	49.1	77.4	(54.7-106.2)
Male	4	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.8	nc	(nc-nc)
Male	10	6.4	157.0	(75.2-288.7)	<u>Testis</u>				
Female	1	3.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.1	nc	(nc-nc)	Male	5	2.3	215.8	(69.6-503.7)
Female	1	0.6	nc	(nc-nc)	Female	4	7.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.4	nc	(nc-nc)	Female	6	10.9	54.9	(20.0-119.4)
Female	2	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	192	174.2	110.2	(95.2-126.9)
Male	3	3.2	nc	(nc-nc)	Female	167	168.3	99.2	(84.8-115.5)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	23.6	127.1	(85.7-181.5)					
Female	28	22.8	122.8	(81.6-177.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.4	104.1	(58.2-171.8)	Male	5	8.9	56.4	(18.2-131.5)
Female	8	5.9	135.5	(58.3-267.0)	Female	6	7.6	79.2	(28.9-172.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.6	65.5	(21.1-152.9)
Female	52	53.7	96.8	(72.3-127.0)	Female	5	7.5	66.3	(21.4-154.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	8	5.4	148.6	(64.0-292.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	20.2	84.2	(49.0-134.8)	Female	5	5.7	87.9	(28.3-205.1)
Female	24	21.7	110.6	(70.8-164.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.3	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	44	52.6	83.6	(60.7-112.2)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	3.3	150.2	(48.4-350.5)
<u>Kidney & Renal Pelvis</u>					Female	2	2.4	nc	(nc-nc)
Male	7	6.7	104.0	(41.7-214.3)	<u>Testis</u>				
Female	5	4.5	111.0	(35.8-258.9)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.3	220.2	(70.9-513.8)	Male	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	8	7.0	113.9	(49.1-224.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.7	nc	(nc-nc)	Female	14	11.8	119.0	(65.0-199.7)
Female	2	4.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	168	189.1	88.8	(75.9-103.3)
Male	3	3.3	nc	(nc-nc)	Female	187	194.1	96.4	(83.0-111.2)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	26.5	113.1	(76.3-161.5)					
Female	23	27.8	82.7	(52.4-124.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.7	123.2	(49.4-253.9)	Male	4	3.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	15	17.3	86.8	(48.6-143.2)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	7	6.0	115.9	(46.4-238.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.7	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	20.9	71.7	(40.1-118.3)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.8	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	61	73.8	82.6	(63.2-106.1)
Male	1	1.3	nc	(nc-nc)	Female	53	59.5	89.1	(66.8-116.6)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	10.5	76.1	(32.8-150.0)					
Female	5	8.4	59.6	(19.2-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	65.9	123.0	(97.6-152.8)	Male	33	39.3	84.0	(57.8-118.0)
Female	34	25.3	134.3	(93.0-187.7)	Female	42	31.7	132.6	(95.5-179.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	11.5	130.9	(73.2-216.0)	Male	8	10.2	78.5	(33.8-154.6)
Female	9	9.9	90.9	(41.5-172.6)	Female	13	8.0	162.4	(86.4-277.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.1	nc	(nc-nc)	Male	36	33.7	106.7	(74.8-147.8)
Female	280	231.9	120.7	(107.0-135.7)	Female	49	32.0	153.1	(113.3-202.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	9.3	118.6	(59.1-212.3)	Male	18	24.2	74.4	(44.1-117.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	121	91.2	132.7	(110.1-158.6)	Female	23	24.4	94.1	(59.6-141.2)
Female	99	91.2	108.6	(88.3-132.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	16	17.0	94.0	(53.7-152.7)	Male	22	19.8	110.9	(69.5-167.9)
Female	3	4.9	nc	(nc-nc)	Female	22	21.8	100.8	(63.2-152.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.6	nc	(nc-nc)	Male	220	248.0	88.7	(77.4-101.2)
Female	3	3.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	35	30.2	115.8	(80.6-161.0)	Male	13	15.0	86.8	(46.2-148.5)
Female	25	19.5	128.4	(83.1-189.5)	Female	5	9.9	50.3	(16.2-117.4)
<u>Larynx</u>					<u>Testis</u>				
Male	13	10.5	123.2	(65.5-210.7)	Male	3	7.4	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	39	20.7	188.0	(133.7-257.0)	Male	9	9.5	95.0	(43.3-180.3)
Female	25	17.0	147.3	(95.3-217.5)	Female	35	28.8	121.4	(84.5-168.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	14.8	128.2	(77.2-200.2)	Female	53	52.3	101.2	(75.8-132.4)
Female	9	5.3	168.4	(76.8-319.7)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	137	122.7	111.7	(93.8-132.0)	Male	914	862.1	106.0	(99.3-113.1)
Female	162	121.7	133.2	(113.4-155.3)	Female	1007	830.3	121.3	(113.9-129.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	9	6.1	148.7	(67.8-282.3)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.3	109.1	(47.0-215.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	3.5	nc	(nc-nc)	Male	21	24.9	84.3	(52.2-128.9)
Female	1	2.6	nc	(nc-nc)	Female	25	19.4	128.8	(83.3-190.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.8	121.5	(72.0-192.0)	Male	14	10.7	131.4	(71.8-220.6)
Female	4	5.2	nc	(nc-nc)	Female	9	8.9	101.7	(46.4-193.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	8.9	191.0	(111.2-305.8)
Female	68	61.6	110.3	(85.7-139.9)	Female	7	7.2	97.1	(38.9-200.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	12	7.0	171.5	(88.5-299.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	22.1	113.3	(73.3-167.3)	Female	4	6.2	nc	(nc-nc)
Female	18	18.4	97.7	(57.9-154.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	4.3	115.6	(37.3-269.8)	Male	70	64.4	108.7	(84.7-137.3)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.2	85.9	(34.4-176.9)	Female	20	13.9	143.6	(87.7-221.8)
Female	3	4.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.7	nc	(nc-nc)	Female	20	13.9	143.6	(87.7-221.8)
Female	1	0.7	nc	(nc-nc)	Male	249	218.8	113.8	(100.1-128.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.4	nc	(nc-nc)	Female	206	201.1	102.4	(88.9-117.4)
Female	3	3.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.0	nc	(nc-nc)	Male	249	218.8	113.8	(100.1-128.9)
Female	0	1.2	nc	(nc-nc)	Female	206	201.1	102.4	(88.9-117.4)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	33	28.9	114.3	(78.7-160.6)	Male	249	218.8	113.8	(100.1-128.9)
Female	37	26.4	140.3	(98.8-193.5)	Female	206	201.1	102.4	(88.9-117.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.9	127.2	(60.9-234.0)	Male	4	6.0	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.6	(32.1-232.5)
Female	31	36.2	85.6	(58.1-121.4)	Female	4	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	5	3.9	128.8	(41.5-300.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	12.0	124.8	(69.8-205.8)	Female	3	3.6	nc	(nc-nc)
Female	4	11.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	6	2.3	260.5	(95.1-567.0)	Female	2	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	32.8	100.7	(69.3-141.5)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.2	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	0.4	nc	(nc-nc)	Female	7	5.9	117.8	(47.2-242.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.0	nc	(nc-nc)	Female	10	7.8	127.5	(61.1-234.6)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	129	117.4	109.9	(91.7-130.5)
Male	2	2.3	nc	(nc-nc)	Female	118	118.0	100.0	(82.7-119.7)
Female	4	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	15.2	105.4	(60.2-171.2)					
Female	14	14.9	94.2	(51.5-158.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	9	11.8	76.0	(34.7-144.2)
Male	0	0.2	nc	(nc-nc)	Female	8	7.7	103.6	(44.6-204.1)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.6	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
Female	10	5.8	172.0	(82.3-316.4)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.6	91.4	(33.4-198.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	3.1	nc	(nc-nc)	Male	31	22.3	139.1	(94.5-197.4)
Female	3	2.9	nc	(nc-nc)	Female	21	20.7	101.5	(62.8-155.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	5.2	135.0	(54.1-278.3)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	8	5.9	134.9	(58.1-265.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	2.7	nc	(nc-nc)	Female	22	21.0	104.8	(65.7-158.7)
Female	4	2.0	nc	(nc-nc)	Female	18	16.5	109.4	(64.8-172.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	59.2	118.2	(92.2-149.4)	Male	40	34.1	117.3	(83.8-159.7)
Female	19	23.8	79.9	(48.1-124.8)	Female	38	28.4	133.8	(94.7-183.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	9.9	141.7	(77.4-237.8)	Male	7	9.0	77.9	(31.2-160.6)
Female	7	8.9	78.4	(31.4-161.5)	Female	5	7.5	66.6	(21.5-155.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	33	29.6	111.6	(76.8-156.7)
Female	209	205.5	101.7	(88.4-116.4)	Female	27	29.7	91.0	(60.0-132.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.0	99.5	(42.8-196.0)	Male	23	20.3	113.4	(71.9-170.2)
Female					Female	13	10.8	120.9	(64.3-206.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	95	80.7	117.7	(95.2-143.9)	Female	19	22.0	86.3	(51.9-134.8)
Female	76	86.8	87.6	(69.0-109.6)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	14.7	129.4	(77.8-202.0)	Male	27	17.5	154.3	(101.6-224.4)
Female	9	4.6	194.2	(88.6-368.7)	Female	21	20.7	101.5	(62.8-155.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.1	nc	(nc-nc)	Male	180	210.4	85.5	(73.5-99.0)
Female	3	3.4	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	26	25.9	100.4	(65.6-147.1)	Male	6	13.5	44.5	(16.3-96.9)
Female	17	17.6	96.4	(56.1-154.4)	Female	5	9.6	52.0	(16.8-121.5)
<u>Larynx</u>					<u>Testis</u>				
Male	6	9.0	66.5	(24.3-144.8)	Male	13	6.5	198.6	(105.6-339.6)
Female	2	2.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	14	18.5	75.6	(41.3-126.9)	Male	5	7.9	62.9	(20.3-146.9)
Female	14	15.9	87.9	(48.0-147.4)	Female	16	24.8	64.6	(36.9-104.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	12.6	126.9	(72.5-206.0)	Female	49	46.0	106.6	(78.8-140.9)
Female	8	5.0	159.9	(68.9-315.1)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	112	107.8	103.9	(85.5-125.0)	Male	762	750.5	101.5	(94.4-109.0)
Female	123	111.6	110.2	(91.6-131.5)	Female	767	756.3	101.4	(94.4-108.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	7	11.6	60.5	(24.2-124.6)
Female	0	0.0	nc	(nc-nc)	Female	9	8.0	112.5	(51.3-213.5)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.2	109.8	(50.1-208.5)	Male	3	5.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.5	154.9	(62.0-319.1)
Female	24	30.3	79.3	(50.8-118.0)	Female	2	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.7	94.4	(47.1-168.9)	Female	1	3.1	nc	(nc-nc)
Female	11	10.4	105.4	(52.5-188.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.5	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	32.1	108.9	(75.9-151.5)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	7	4.1	172.2	(69.0-354.9)	<u>Testis</u>				
Female	4	2.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	8	6.8	117.6	(50.6-231.8)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	117	112.3	104.2	(86.1-124.8)
Male	0	2.0	nc	(nc-nc)	Female	95	103.8	91.5	(74.0-111.9)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	15.5	83.7	(44.5-143.1)					
Female	15	14.6	103.0	(57.6-169.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	52.9	109.6	(83.2-141.7)	Male	67	34.9	191.7	(148.6-243.5)
Female	23	19.8	116.1	(73.6-174.2)	Female	42	29.0	144.9	(104.4-195.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	10.8	83.2	(38.0-158.0)	Male	13	8.5	153.0	(81.4-261.6)
Female	9	9.0	100.4	(45.8-190.5)	Female	8	6.4	125.7	(54.1-247.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	33	29.7	111.0	(76.4-155.9)
Female	224	202.9	110.4	(96.4-125.9)	Female	24	26.3	91.1	(58.4-135.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	9.1	98.9	(45.1-187.7)	Male	21	21.7	96.6	(59.8-147.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	89	76.1	117.0	(93.9-143.9)	Female	17	21.1	80.7	(47.0-129.2)
Female	83	73.4	113.0	(90.0-140.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	16.3	141.5	(89.7-212.3)
Male	16	14.2	112.9	(64.5-183.4)	Female	21	17.2	121.9	(75.4-186.3)
Female	6	3.8	156.2	(57.0-339.9)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	271	202.5	133.9	(118.4-150.8)
Male	4	5.1	nc	(nc-nc)	<u>Stomach</u>				
Female	5	3.8	131.3	(42.3-306.5)	Male	12	12.4	97.0	(50.1-169.5)
<u>Kidney & Renal Pelvis</u>					Female	6	8.0	74.7	(27.3-162.6)
Male	36	26.1	137.8	(96.5-190.7)	<u>Testis</u>				
Female	26	16.0	162.2	(105.9-237.6)	Male	9	9.0	99.7	(45.5-189.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	8.8	91.0	(39.2-179.3)	Male	6	9.4	63.7	(23.3-138.7)
Female	3	2.4	nc	(nc-nc)	Female	31	28.9	107.4	(73.0-152.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	18.3	120.4	(75.4-182.2)	Female	54	44.9	120.2	(90.3-156.9)
Female	30	14.5	207.4	(139.9-296.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	884	723.7	122.2	(114.2-130.5)
Male	12	13.0	92.3	(47.7-161.3)	Female	777	700.5	110.9	(103.3-119.0)
Female	9	4.3	207.0	(94.5-393.0)					
<u>Lung and Bronchus</u>									
Male	125	98.0	127.6	(106.2-152.0)					
Female	91	94.6	96.2	(77.5-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	11	9.4	116.4	(58.0-208.3)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.4	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	10	10.0	100.5	(48.1-184.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.7	nc	(nc-nc)	Male	36	33.7	106.7	(74.7-147.7)
Female	0	0.2	nc	(nc-nc)	Female	36	29.7	121.3	(84.9-167.9)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	4.4	nc	(nc-nc)					
Female	6	3.6	166.7	(60.9-362.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.1	195.1	(71.2-424.7)	Male	4	2.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	13	12.4	104.5	(55.6-178.7)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	4.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	13	13.1	99.0	(52.6-169.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	2	0.9	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	6.0	100.6	(36.7-218.9)	Female	43	45.6	94.4	(68.3-127.2)
Female	0	4.8	nc	(nc-nc)	Female	29	38.9	74.6	(50.0-107.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	5.1	235.1	(121.3-410.7)	Male	5	3.2	154.4	(49.8-360.4)
Female	2	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	13	16.0	81.2	(43.2-138.9)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	6	2.0	302.8	(110.6-659.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	7.3	220.5	(126.0-358.1)	Female	1	1.7	nc	(nc-nc)
Female	8	6.4	124.9	(53.8-246.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	21	18.8	111.9	(69.3-171.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.4	nc	(nc-nc)	Female	5	3.5	142.3	(45.9-332.2)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	0.8	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	1.2	494.4	(180.5-1076.2)	Male	11	9.3	117.9	(58.8-210.9)
Female	0	0.4	nc	(nc-nc)	Female	15	7.9	189.0	(105.7-311.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	88	105.5	83.4	(66.9-102.8)	Male	66	64.3	102.7	(79.4-130.6)
Female	44	42.7	103.1	(74.9-138.4)	Female	56	55.7	100.6	(76.0-130.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	18.9	95.4	(56.5-150.8)	Male	16	16.3	98.2	(56.1-159.6)
Female	15	16.9	88.6	(49.5-146.1)	Female	16	13.5	118.8	(67.8-192.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.3	nc	(nc-nc)	Male	55	55.0	100.0	(75.3-130.2)
Female	362	387.2	93.5	(84.1-103.6)	Female	53	54.3	97.5	(73.0-127.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	16.6	126.7	(78.4-193.7)	Male	43	38.2	112.7	(81.5-151.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	169	146.0	115.8	(99.0-134.6)	Female	38	41.1	92.5	(65.4-126.9)
Female	170	155.3	109.5	(93.6-127.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	30	26.8	112.0	(75.6-159.9)	Male	29	31.5	92.1	(61.7-132.2)
Female	5	8.3	60.3	(19.4-140.7)	Female	39	36.9	105.6	(75.1-144.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	8.7	126.8	(63.2-226.9)	Male	277	385.4	71.9	(63.7-80.8)
Female	7	7.2	97.4	(39.0-200.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	44	48.1	91.4	(66.4-122.8)	Male	31	24.2	128.1	(87.0-181.8)
Female	24	32.5	73.8	(47.2-109.8)	Female	16	17.1	93.4	(53.4-151.7)
<u>Larynx</u>					<u>Testis</u>				
Male	19	16.6	114.7	(69.0-179.2)	Male	13	15.5	83.8	(44.6-143.3)
Female	9	4.8	187.8	(85.7-356.6)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	26	33.9	76.7	(50.1-112.4)	Male	13	16.1	80.6	(42.9-137.8)
Female	26	29.1	89.3	(58.3-130.9)	Female	60	51.9	115.7	(88.3-148.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	37	23.4	158.3	(111.4-218.2)	Female	90	86.3	104.2	(83.8-128.1)
Female	11	9.1	121.4	(60.5-217.2)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	201	193.8	103.7	(89.9-119.1)	Male	1301	1375.4	94.6	(89.5-99.9)
Female	234	202.4	115.6	(101.3-131.4)	Female	1431	1403.0	102.0	(96.8-107.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	33.8	94.7	(64.8-133.7)	Male	13	21.4	60.7	(32.3-103.9)
Female	12	12.6	95.6	(49.3-166.9)	Female	10	18.1	55.2	(26.4-101.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.5	122.3	(52.7-241.1)	Male	5	5.3	93.7	(30.2-218.6)
Female	4	5.6	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	25	18.3	136.7	(88.4-201.8)
Female	121	126.4	95.7	(79.4-114.4)	Female	14	16.5	84.9	(46.4-142.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.7	nc	(nc-nc)	Male	6	13.2	45.3	(16.6-98.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	47.8	85.8	(61.5-116.4)	Female	23	13.1	175.3	(111.1-263.0)
Female	61	45.5	134.0	(102.5-172.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	10.3	58.4	(21.3-127.0)
Male	8	8.9	89.8	(38.7-177.0)	Female	18	10.8	166.5	(98.6-263.2)
Female	1	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	123	128.1	96.0	(79.8-114.6)
Male	3	2.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.4	nc	(nc-nc)	Male	8	7.8	102.4	(44.1-201.8)
<u>Kidney & Renal Pelvis</u>					Female	12	4.9	242.9	(125.4-424.3)
Male	15	16.2	92.4	(51.7-152.4)	<u>Testis</u>				
Female	11	10.1	108.6	(54.1-194.3)	Male	2	4.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	5.5	90.6	(29.2-211.5)	Male	8	5.5	144.3	(62.1-284.3)
Female	3	1.5	nc	(nc-nc)	Female	19	18.1	105.2	(63.3-164.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	11.3	79.7	(36.4-151.3)	Female	29	28.1	103.2	(69.1-148.2)
Female	9	9.0	100.3	(45.8-190.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	433	453.7	95.4	(86.7-104.9)
Male	10	8.0	125.0	(59.8-229.8)	Female	483	438.8	110.1	(100.5-120.3)
Female	1	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	72	62.9	114.4	(89.5-144.1)					
Female	86	60.8	141.4	(113.1-174.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.5	118.6	(67.7-192.6)	Male	11	8.6	127.2	(63.4-227.7)
Female	1	5.1	nc	(nc-nc)	Female	9	7.4	122.3	(55.8-232.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.4	122.0	(55.7-231.6)
Female	45	52.1	86.4	(63.0-115.6)	Female	1	6.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	6	5.4	110.1	(40.2-239.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	19.3	114.2	(71.6-173.0)	Female	7	5.4	129.7	(51.9-267.2)
Female	11	18.6	59.2	(29.5-105.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.1	144.8	(52.9-315.2)
Male	3	3.6	nc	(nc-nc)	Female	0	4.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	52.4	112.7	(85.8-145.4)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	0.9	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.0	nc	(nc-nc)
Male	7	6.6	106.1	(42.5-218.5)	<u>Testis</u>				
Female	3	4.2	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	5	7.3	68.4	(22.1-159.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.5	nc	(nc-nc)	Female	7	11.7	60.0	(24.0-123.6)
Female	3	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	199	183.5	108.5	(93.9-124.6)
Male	4	3.3	nc	(nc-nc)	Female	144	179.7	80.1	(67.6-94.3)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	25.3	91.0	(57.7-136.6)					
Female	29	24.8	116.9	(78.3-167.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	26.3	113.9	(76.8-162.6)	Male	19	16.4	115.5	(69.5-180.4)
Female	16	10.1	159.0	(90.8-258.2)	Female	17	13.7	124.5	(72.5-199.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.0	179.8	(82.1-341.4)	Male	3	4.1	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	14.1	78.2	(39.0-139.9)
Female	131	99.0	132.3	(110.6-157.0)	Female	10	13.0	77.0	(36.9-141.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.2	nc	(nc-nc)	Male	10	10.2	98.3	(47.0-180.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	37.1	80.9	(54.5-115.4)	Female	10	10.3	97.4	(46.6-179.1)
Female	45	36.5	123.4	(90.0-165.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.0	87.6	(35.1-180.4)
Male	4	6.9	nc	(nc-nc)	Female	9	8.7	103.7	(47.3-196.9)
Female	3	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	116	99.1	117.0	(96.7-140.4)
Male	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.6	nc	(nc-nc)	Male	7	6.1	115.4	(46.2-237.8)
<u>Kidney & Renal Pelvis</u>					Female	4	4.0	nc	(nc-nc)
Male	8	12.6	63.5	(27.3-125.1)	<u>Testis</u>				
Female	8	8.0	99.9	(43.0-196.8)	Male	4	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.3	nc	(nc-nc)	Male	5	4.2	119.4	(38.5-278.6)
Female	0	1.2	nc	(nc-nc)	Female	17	13.2	129.1	(75.2-206.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	8.7	57.7	(18.6-134.6)	Female	17	22.0	77.2	(45.0-123.7)
Female	8	7.0	113.7	(49.0-224.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	344	350.8	98.1	(88.0-109.0)
Male	8	6.2	129.4	(55.7-255.1)	Female	373	344.6	108.2	(97.5-119.8)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	49.1	91.6	(66.8-122.5)					
Female	40	48.6	82.4	(58.8-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.3	145.8	(81.5-240.5)	Male	14	7.3	192.3	(105.1-322.7)
Female	5	3.5	142.1	(45.8-331.7)	Female	5	5.8	86.0	(27.7-200.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.1	131.1	(56.5-258.4)
Female	44	41.4	106.4	(77.3-142.8)	Female	6	4.8	124.3	(45.4-270.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	5	4.9	102.9	(33.1-240.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	15.4	71.4	(35.6-127.8)	Female	4	4.2	nc	(nc-nc)
Female	12	12.7	94.2	(48.6-164.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	43.6	128.3	(96.9-166.6)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	8	5.6	142.7	(61.5-281.2)	<u>Testis</u>				
Female	5	3.1	161.8	(52.1-377.6)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.9	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	6.3	112.0	(44.9-230.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.6	165.9	(60.6-361.2)	Female	6	9.2	65.3	(23.9-142.2)
Female	6	2.6	231.4	(84.5-503.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	160	149.8	106.8	(90.9-124.7)
Male	3	2.8	nc	(nc-nc)	Female	137	134.7	101.7	(85.4-120.2)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	19.9	60.3	(31.1-105.4)					
Female	18	17.5	102.6	(60.8-162.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	69	55.3	124.9	(97.1-158.0)	Male	21	33.0	63.5	(39.3-97.1)
Female	32	21.3	150.5	(102.9-212.5)	Female	29	27.5	105.6	(70.7-151.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	9.8	112.0	(55.8-200.4)	Male	10	8.4	118.4	(56.7-217.8)
Female	11	8.6	128.6	(64.1-230.1)	Female	7	6.7	104.6	(41.9-215.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	32	28.4	112.5	(76.9-158.8)
Female	183	191.1	95.8	(82.4-110.7)	Female	27	27.0	100.0	(65.9-145.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.3	108.9	(49.7-206.8)	Male	22	19.4	113.4	(71.1-171.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	77	75.8	101.6	(80.2-127.0)	Female	18	20.3	88.6	(52.5-140.1)
Female	92	77.0	119.4	(96.3-146.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	16.4	121.9	(74.4-188.2)
Male	13	13.9	93.7	(49.8-160.2)	Female	24	18.3	130.9	(83.8-194.8)
Female	4	4.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	163	199.0	81.9	(69.8-95.5)
Male	7	4.4	160.7	(64.4-331.2)	<u>Stomach</u>				
Female	6	3.5	170.0	(62.1-370.0)	Male	14	12.6	111.0	(60.7-186.3)
<u>Kidney & Renal Pelvis</u>					Female	14	8.5	164.4	(89.8-275.9)
Male	36	24.9	144.7	(101.3-200.3)	<u>Testis</u>				
Female	23	16.2	141.9	(89.9-212.9)	Male	9	7.7	117.3	(53.5-222.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	8.5	105.3	(48.0-199.9)	Male	10	8.2	122.5	(58.6-225.2)
Female	1	2.4	nc	(nc-nc)	Female	30	25.6	117.0	(78.9-167.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	17.8	106.9	(64.3-167.0)	Female	47	42.6	110.3	(81.0-146.7)
Female	19	14.7	129.5	(77.9-202.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	746	712.9	104.6	(97.3-112.4)
Male	10	11.9	83.8	(40.1-154.1)	Female	770	695.8	110.7	(103.0-118.8)
Female	7	4.5	155.0	(62.1-319.4)					
<u>Lung and Bronchus</u>									
Male	138	101.5	136.0	(114.3-160.7)					
Female	118	100.9	116.9	(96.8-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	7	8.1	86.4	(34.6-178.1)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	9.6	156.8	(87.7-258.6)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	37	31.6	117.2	(82.5-161.5)
Male	1	0.6	nc	(nc-nc)	Female	25	27.1	92.2	(59.7-136.1)
Female	1	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	4.4	113.2	(36.5-264.3)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.6	131.2	(47.9-285.6)	Male	4	3.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	4	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	14	18.4	76.1	(41.6-127.6)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	6.9	72.3	(23.3-168.7)	Female	3	1.8	nc	(nc-nc)
Female	2	5.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	17	19.4	87.5	(50.9-140.1)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.7	nc	(nc-nc)	Female	6	4.0	148.7	(54.3-323.7)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	59	67.3	87.7	(66.8-113.2)
Male	0	1.3	nc	(nc-nc)	Female	51	59.2	86.2	(64.1-113.3)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	8.8	67.9	(24.8-147.8)					
Female	7	7.5	92.8	(37.2-191.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.8	112.4	(68.7-173.7)	Male	13	11.3	115.0	(61.2-196.7)
Female	7	7.3	96.4	(38.6-198.6)	Female	10	10.1	98.8	(47.3-181.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	10	9.7	103.6	(49.6-190.4)
Female	62	71.4	86.9	(66.6-111.4)	Female	7	9.4	74.3	(29.7-153.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	25.1	123.6	(83.9-175.4)	Female	11	7.4	148.1	(73.8-264.9)
Female	27	25.9	104.2	(68.7-151.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.4	nc	(nc-nc)
Male	6	4.7	127.9	(46.7-278.3)	Female	11	6.2	177.4	(88.4-317.4)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	57	68.1	83.7	(63.4-108.5)
Male	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	5	4.1	122.3	(39.4-285.3)
<u>Kidney & Renal Pelvis</u>					Female	0	2.8	nc	(nc-nc)
Male	15	8.6	174.4	(97.5-287.6)	<u>Testis</u>				
Female	4	5.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	11	9.9	110.8	(55.3-198.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.0	116.7	(46.7-240.4)	Female	18	16.1	111.8	(66.2-176.7)
Female	3	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	254	240.2	105.8	(93.2-119.6)
Male	6	4.2	143.2	(52.3-311.8)	Female	256	249.7	102.5	(90.3-115.9)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	33.5	122.6	(87.9-166.3)					
Female	54	35.5	152.0	(114.2-198.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.6	120.8	(66.0-202.8)	Male	9	6.7	135.0	(61.6-256.4)
Female	3	4.7	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.8	86.7	(27.9-202.2)
Female	36	42.4	84.9	(59.4-117.5)	Female	5	5.9	84.8	(27.3-198.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	16.0	112.8	(66.8-178.2)	Female	8	4.5	178.7	(76.9-352.0)
Female	13	17.3	75.3	(40.1-128.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	6	4.1	146.3	(53.4-318.4)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	41.2	97.1	(69.3-132.2)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	1.9	nc	(nc-nc)
Male	2	5.1	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.6	nc	(nc-nc)	Female	9	9.5	94.6	(43.1-179.5)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	144	146.5	98.3	(82.9-115.7)
Male	0	2.5	nc	(nc-nc)	Female	142	152.0	93.4	(78.7-110.1)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	20.8	86.3	(51.1-136.5)					
Female	26	22.2	117.3	(76.6-171.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	8.0	125.6	(60.1-231.0)
Male	0	0.1	nc	(nc-nc)	Female	10	6.4	156.7	(75.0-288.2)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	1.1	nc	(nc-nc)					
Female	3	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	108.1	(34.8-252.3)	Male	2	3.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.8	177.2	(57.1-413.5)
Female	21	20.3	103.6	(64.1-158.4)	Female	5	2.5	202.6	(65.3-472.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.9	86.8	(31.7-188.9)	Female	3	2.1	nc	(nc-nc)
Female	3	6.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.5	nc	(nc-nc)
Male	5	1.3	382.2	(123.2-891.9)	Female	0	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	18.5	113.3	(70.1-173.1)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.7	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	73	66.6	109.6	(85.9-137.8)
Male	1	1.3	nc	(nc-nc)	Female	59	67.6	87.3	(66.4-112.6)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.7	80.3	(32.2-165.4)					
Female	12	8.6	139.1	(71.8-242.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	4.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	13	17.4	74.7	(39.8-127.8)
Male	0	0.3	nc	(nc-nc)	Female	7	14.5	48.2	(19.3-99.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;